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Abstract
Background: Contacts of leprosy patients are at increased risk of developing leprosy and need to be targeted for early
diagnosis. Seropositivity to the phenolic glycolipid I (PGL-I) antigen of Mycobacterium leprae has been used to identify
contacts who have an increased risk of developing leprosy. In the present study, we studied the effect of seropositivity in
patient contacts, on the risk of developing leprosy, stratified by Bacille Calmette Guerin (BCG) vaccination after index case
diagnosis.
Methodology/Principal Findings: Leprosy contacts were examined as part of the surveillance programme of the Oswaldo
Cruz Institute Leprosy Outpatient Clinic in Rio de Janeiro. Demographic, social, epidemiological and clinical data were
collected. The presence of IgM antibodies to PGL-I in sera and BCG vaccination status at the time of index case diagnosis
were evaluated in 2,135 contacts. During follow-up, 60 (2.8%; 60/2,135) leprosy cases were diagnosed: 41 among the 1,793
PGL-I-negative contacts and 19 among the 342 PGL-I-positive contacts. Among PGL-I-positive contacts, BCG vaccination
after index case diagnosis increased the adjusted rate of developing clinical manifestations of leprosy (Adjusted Rate Ratio
(aRR)=4.1; 95% CI: 1.8–8.2) compared with the PGL-I-positive unvaccinated contacts (aRR=3.2; 95% CI: 1.2–8.1). The
incidence density was highest during the first year of follow-up for the PGL-I-positive vaccinated contacts. However, all of
those contacts developed PB leprosy, whereas most MB cases (4/6) occurred in PGL-I-positive unvaccinated contacts.
Conclusion: Contact examination combined with PGL-I testing and BCG vaccination remain important strategies for leprosy
control. The finding that rates of leprosy cases were highest among seropositive contacts justifies targeting this specific
group for close monitoring. Furthermore, it is recommended that PGL-I-positive contacts and contacts with a high familial
bacteriological index, regardless of serological response, should be monitored. This group could be considered as a target
for chemoprophylaxis.
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Introduction
It was widely expected that the treatment of all newly diagnosed
leprosy cases with multidrug therapy (MDT) would not only cure
the disease but also prevent the further spread of Mycobacterium
leprae (M. leprae). In fact, from 2004 to 2010, the number of newly
diagnosed cases worldwide fell by 44%. Nonetheless, incidence
rates above 1 case in 10,000 remain in a few countries, namely
Brazil, Nepal, Liberia, and a few islands in the Western Pacific.
Brazil reported the most cases in the Americas and the second
most worldwide in 2010 [1]. Of the 34,894 new leprosy patients
diagnosed in Brazil in 2010, 5.36% were children under 15, an
indication that the transmission of M. leprae is ongoing [2].
Notably, 7.2% of the newly detected leprosy cases were of
disability grade 2 [3], demonstrating the heretofore limited
effectiveness of case detection and the magnitude of the hidden
prevalence of leprosy [4].
Maintenance of poverty and of the intensity of exposure may
have contributed to the low effectiveness of leprosy control
programs. Even if the effectiveness of case detection and MDT
treatment could be improved, additional interventions would be
needed, with a special focus on groups at particularly high risk of
developing clinical leprosy [5]. It has long been known that
contacts of leprosy patients have an increased risk of developing
leprosy compared with the general population [6].
The detection of antibodies to the phenolic glycolipid I (PGL-I)
antigen of M. leprae has been used to understand the epidemiology
of subclinical infection, as opposed to active disease. However, this
technique has not been proven for the early diagnosis of clinical
cases and for predicting who (either among contacts of known
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leprosy in the future [7]. The relationship between PGL-I
seroprevalence and the leprosy burden depends on the population
studied [8,9]. Seropositivity has been reported to be higher in
contacts of leprosy patients than among the general population
and has been associated with the development of leprosy [10,11].
Although PGL-I (2) based serological tests cannot be used as
screening tools in the general population, they have been used to
identify contacts of leprosy patients who have a higher risk of
developing leprosy [12]. After 7 years of follow-up of a cohort of
559 household contacts of multibacillary (MB) patients with a
bacteriological index (BI) greater than or equal to 2, Douglas et al.
[13] reported that seropositive (PGL-I (+)) contacts in the
Philippines had a 7-fold higher risk of developing leprosy
compared with seronegative (PGL-I (2)) contacts. The Yalisombo
Study Group [14] reported a slightly higher proportion of cases
among PGL-I (+) (1/189; 0.53%) compared with PGL-I (2)
contacts (10/3018; 0.33%) in a survey of 4 hyperendemic villages
in Zaire. Other studies have not reported an increased risk of
developing leprosy among seropositive contacts [15,16].
The Brazilian Leprosy Control Program has recommended that
all household contacts of leprosy patients be examined and receive
Bacille Calmette Guerin (BCG) immunization as an additional
preventive measure against leprosy [17]. According to Bagshawe
et al. [18], the accelerated manifestations of benign tuberculoid
leprosy after BCG vaccination reflect BCG vaccination acceler-
ation of the natural history of M. leprae infection in individuals who
were infected prior to or immediately after vaccination. In line
with this result, Duppre et al. [19] found that vaccinated contacts
contracted leprosy mainly from MB index cases (ICs), suggesting
the presence of subclinical infection which becomes overt due to
vaccination induced immune response activation.
Because previous studies have failed to reach a consensus
regarding the effect of seropositivity on the risk of developing
leprosy among contacts and the degree of protection conferred by
prior BCG vaccination (BCG scar), further investigation seemed
necessary. Thus, the effects of simultaneous BCG vaccination and
other possible covariates on the diagnosis of overt leprosy were
studied in a group of contacts participating in a surveillance
program. The effect of PGL-I seropositivity in contacts, adjusted
by covariates measured at the first examination, on the risk of
developing leprosy was assessed per se and according to BCG
vaccination status after IC diagnosis.
Materials and Methods
Study design
This dynamic cohort study was based on the contact
surveillance programme of leprosy patients who were diagnosed
at the Leprosy Outpatient Clinic of the Oswaldo Cruz Institute,
FIOCRUZ, in Rio de Janeiro, RJ, Brazil. Among the 6,060
contacts examined between June 1987 and December 2007, 2,135
(35.2%) were tested for IgM antibodies to PGL-I. During this
period, 2.2% (46/2,135) of the contacts were diagnosed at the
initial examination (co-prevalent cases), did not receive the BCG
vaccine and were excluded from the present study. The subsample
of contacts selected for the present study was similar to the
contacts not selected in terms of gender (p=0.61), operational
classification of IC (p=0.87) and presence of BCG vaccination
scar (p=0.98). However, the selected group of contacts was
significantly older than those contacts who were not selected
(p,0.001). The possible selection bias toward older contacts could
be due to the difficulties of blood sampling in children. Most
parents refused to allow the collection of blood from their children.
Blood sampling in young children became part of the protocol
after the introduction of the ML Flow test, which uses only one
drop of blood for testing.
The presence of anti-PGL-I antibodies at the first examination
was the primary variable of interest. The modifying effect of BCG
vaccination after IC diagnosis was highlighted because of its
known association with the study outcome.
Household contacts were defined as individuals who lived in the
same dwelling (i.e., sharing the same kitchen or social/recreational
area). Non-household contacts were defined as those indicated by
the IC as having had other types of associations, such as next-door
neighbors, blood relatives, friends and colleagues. The duration of
association with the IC was not considered during the selection of
contacts.
Contact examination
After confirmation of the leprosy diagnosis, patients were given
educational information about the disease, and medical visits were
scheduled for their close contacts (within and outside of the
household). During the initial visit, contacts were interviewed by a
social worker to obtain demographic and social information (e.g.,
schooling and individual and family income) and the degree of
closeness to the IC. All contacts received health education on
leprosy and were instructed to report to the Leprosy Outpatient
Clinic if any clinical signs of leprosy occurred. In addition, contacts
were instructed to visit the Center once a year for a period of 3–5
years. In general, contacts were followed for at least 2 years, and
the follow-up period ended in December 2009.
An experienced clinical dermatologist examined all of the
contacts to identify any leprosy lesions and the typical BCG
vaccine scar. In addition, a neurological exam of peripheral nerves
was performed by a qualified physiotherapist or neurologist. If a
contact presented signs and symptoms suggestive of leprosy, he or
she was assessed by bacteriological, histopathological, and
immunological tests. If leprosy was diagnosed, the individual was
classified according to the Ridley and Jopling scale [20] and
grouped for treatment according to the bacteriological index (BI)
Author Summary
Although leprosy has become a neglected disease, it is an
important cause of disability, and 250,000 new cases are
still diagnosed worldwide every year. The current study
was carried out in Brazil, where almost 40,000 new cases of
leprosy are diagnosed every year. The study targeted
contacts of leprosy patients, who are at the highest risk of
contracting the disease. We studied 2,135 contacts who
were diagnosed at the Leprosy Outpatient Clinic at the
Oswaldo Cruz Foundation in Rio de Janeiro, RJ, Brazil,
between 1987 and 2007. The presence of antibodies
against a specific Mycobacterium leprae antigen (PGL-I) at
the first examination and BCG vaccination status were
evaluated. PGL-I-positive contacts had a higher risk of
developing leprosy than PGL-I-negative contacts. Among
the former, vaccinated contacts were at higher risk than
unvaccinated contacts. Our results indicate that contact
examination combined with PGL-I testing and BCG
vaccination appears to justify the targeting of PGL-I-
positive individuals for enhanced surveillance. Further-
more, it is highly recommended that PGL-I-positive
contacts and contacts with a high familial bacterial index
(i.e., the sum of results from index and co-prevalent cases),
regardless of serological response, should be monitored.
This group could be considered as a target for chemo-
prophylaxis.
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(PB - negative BI).
BCG vaccination
Since 1991, the BCG vaccine has been administered to all
healthy contacts, as recommended by the Brazilian Leprosy
Control Program [21]; however, 248 (12.8%) of the contacts in the
sample group were not vaccinated at their first visit due to
pregnancy, acute disease or vaccine shortage. These contacts were
rescheduled for vaccination, but 179 (111 of whom had a BCG
vaccine scar and 68 of whom had no visible scar) failed to return
for vaccination. These noncompliant cases, together with 200
contacts examined before 1991 (104 with a BCG scar and 96
without), were included in the study as part of the unvaccinated
group. Thus, among the 2,135 contacts included in this study,
1,756 received simultaneous BCG vaccine at the time of IC
diagnosis, and 379 did not.
PGL-I serology
Before vaccination, blood samples were collected, and the sera
were separated into aliquots, followed by storage at 220uC to later
determine the presence/absence of anti-PGL-I antibodies (all
contacts were eligible).
Two different rapid tests were used for evaluation of the
presence of antibodies in blood serum. The ML Dipstick assay
[22] was used between 1987 and 2002 to test 1,050 contacts.
Beginning in 2003, the ML Flow test was implemented as part of
the routine contact examination, and 1,085 contacts were tested in
this manner.
The visual readings of both tests were performed as previously
described [22]. A reddish-stained antigen band indicated a positive
reaction. Both tests presented a high level of agreement in the
detection of IgM antibodies to PGL-I using the enzyme-linked
immunosorbent assay (ELISA) (97.2% [k=0.92] and 91%
[k=0.77] for the ML Dipstick and ML Flow tests, respectively)
[12].
Case detection
For the purposes of this study, those contacts who did not return
for evaluation were considered free of leprosy. However, due to
the low participation of contacts in re-examination during the
study period (29%), a complementary strategy was adopted. To
ascertain the existence of leprosy contacts who might have moved
away or visited another health center, the Brazilian Information
System for Notifiable Diseases (SINAN) database was searched for
new cases. Reporting cases to the SINAN is compulsory for all
municipalities in Brazil and is performed on a weekly basis. The
data feed is monitored at the state and national levels according to
specific parameters.
SINAN records published in 2010 (i.e., with data on new cases
up to 2009) were matched to the database of the present study by
the contact’s full name, date of birth, and mother’s full name. As a
result of this search, 3 contacts in the SINAN database were
included in the sample group as new leprosy cases.
Ethics statement
After receiving educational information about leprosy, all adult
participants and the guardians or parents of the child participants
provided written consent. A medical history for each contact was
taken from routine care medical records. Data collection,
management, and analysis were performed by the study coordi-
nators, and confidentiality was maintained throughout the
research. The present study, including the use of patient records,
was approved by the Research Ethics Committee of the National
School of Public Health (Document Nu. 113/06).
Statistical analysis
The leprosy incidence rate at the contact follow-up was based
on person-years (PYs) between the first examination of a contact
and the date of his or her leprosy diagnosis. Contacts who did not
return for follow-up or who were not found in the SINAN
database were considered to be free of leprosy at the end of the
study.
The total familial BI was derived from the sum of all BIs of MB
cases in the family at the time of the first examination, which was
believed to be a better proxy of disease risk for the contacts who
were followed up after the initial examination.
Contacts who did not receive the BCG vaccine after the IC’s
diagnosis were considered unvaccinated, and those who were
vaccinated subsequent to the IC’s diagnosis were considered
vaccinated. Accordingly, based on their vaccination status and
serological response to PGL-I, the contacts were grouped into the
following categories: PVC, Positive Vaccinated Contacts; NVC,
Negative Vaccinated Contacts; PUC, Positive Unvaccinated
Contacts; and NUC, Negative Unvaccinated Contacts.
The association between covariates and seropositivity was
analyzed using univariate and multivariate logistic regression to
generate odds ratios (ORs). Crude and adjusted rate ratios (RRs)
were estimated by Poisson regression to verify the association
between seropositivity and the development of leprosy, both
overall and stratified according to vaccination status. RR estimates
were adjusted for age, gender, presence of BCG scar, type of
association with the IC, duration of close association with the IC,
and sum of the family BIs. The 95% confidence intervals (CIs)
were determined for all estimates. Multivariate analyses and CIs
were based on robust variance estimators using clusters of
contacts. To account for the clustering effect in both types of
regressions, the CI was based on robust variance estimators that
account for a smaller variance of contacts clustered around the IC.
Statistical interaction (RR test of homogeneity) was assessed when
judged scientifically meaningful according to the Mantel-Haenszel
test.
Statistical analysis was performed with Stata
TM version 8.0
(Stata Corp., College Station, TX,USA) and Open Source
Epidemiologic Statistics for Public Health version 2.3.1 (http://
www.openepi.com/OE2.3/Menu/OpenEpiMenu.htm).
Results
The present study included 2,135 contacts of 668 ICs (220 PB
and 448 MB, with an average of 3.5 contacts per MB patient and
2.6 per PB patient) who were tested for the presence of IgM
antibodies to PGL-I from 1987 to 2009. Most of the contacts
(1,253; 59%) were female. The mean age was 28.8 (SD: 17.0)
years. Most of the contacts (64%) had a low monthly family
income (below four minimum salaries defined by law and adjusted
periodically according to inflation.
There were no demographic differences between the vaccinated
and unvaccinated contacts. In both groups, females predominated
(58.3% of vaccinated contacts and 60.4% of unvaccinated
contacts). The mean age was significantly greater (t-test=2.04;
p=0.042) in vaccinated contacts (29.2617.2 years) compared with
unvaccinated contacts (27.2616.2 years).
Overall, the rate of seropositivity to PGL-I at the first evaluation
was 16.0% among contacts. Adjusting for relevant covariates,
seropositivity was more frequent among household contacts,
females, contacts aged 15–35 years, and contacts with a high
PGL-I Serology and BCG Vaccination
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duration of close association with the IC and the operational
classification of the IC did not appear to influence PGL-I positivity
(Table 1).
The contacts were followed for an average of 5.163.98 years
(range: 0.21–18 years). During the follow-up period, 60 (28.1/
1,000 PYs) new cases of leprosy were diagnosed at an incidence
density of 5.08/1,000 PYs. Most of the cases (90%; 54/60) were
contacts of MB patients. The average latency of detection of the
new cases after the initial examination was 2.8 years (range: 3
months-10.5 years). Only 11 cases were detected during the first
year after initial examination. The rate of detection declined
steeply between the first and fourth years after the initial
examination of contacts (Figure 1, solid line).
The incidence density of leprosy varied according to the BCG
vaccination status and serology result (Figure 1, broken lines).
PVCs and NUCs had the highest incidences of leprosy during the
first year of follow-up at 17.9/1,000 PYs and 9.9/1,000 PYs,
respectively. The effectiveness of the BCG vaccination was
identified at the 2-year follow-up, rapidly reducing the incidence
density to 2.5/1,000 PYs. However, the incidence density in
NUCs did not begin to decrease until the third year. In addition,
the incidence density was low during the initial years of follow-up
in NVCs and progressively decreased, reaching 0 at 5 years of
follow-up. Conversely, no cases of leprosy were diagnosed in the
PUC group during the first 2 years of follow-up. However, the
incidence density progressively increased in this group of contacts,
with the highest values identified in the sixth year of follow-up. All
of the groups converged to zero incidence during the 11th year of
follow-up.
Leprosy diagnosis was strongly associated with PGL-I seropos-
itivity. A significantly higher (x
2=11.2; p,0.01) proportion of
incident cases was detected among PGL-I (+) contacts (5.6%, 19/
342) during the follow-up period compared with PGL-I (2)
contacts (2.3%; 41/1,793). PGL-I (+) contacts presented a 3.2-fold
(95% CI: 1.6–6.1) higher risk for leprosy compared with PGL-I
(2) contacts.
Stratification by vaccination status showed that the rate of
developing leprosy was 1.8 times higher among unvaccinated than
vaccinated contacts (8.3/4.6; p=0.03). Among PGL-I (+) contacts,
BCG vaccination after IC diagnosis increased the adjusted rate of
developing clinical manifestations of leprosy (aRR=4.1; 95% CI:
1.8–8.2) compared with the PGL-I (+) unvaccinated contacts
(aRR=3.2; 95% CI: 1.2–8.1).
Table 1. Crude and adjusted measures of association of seropositivity and selected covariates among leprosy contacts.
Serology anti PGL-I Odds ratio (95% C.I.)
3
Covariates n PGL-I (+) (n%) p value
1 Unadjusted Adjusted
2
All contacts Previous BCG scar 2,135 342 (16.0) - - -
N Without BCG scar 782 108 (13.8) 1 1
N With BCG scar 1,353 234 (17.3) 0.03 1.3 (1.0–1.7) 0.9 (0.6–1.2)
Gender
Male 882 120 (13.6) 1 1
N Female 1,253 222 (17.7) 0.01 1.4 (1.1–1.7) 1.4 (1.1–1.8)
Age group
N 0–14 years 494 73 (14.8) 1.2 (0.9–1.8) 1.1 (0.7–1.8)
N 15–35 years 1,092 211 (19.3) 1.7 (1.3–2.3) 1.7 (1.2–2.4)
N 36 years and over 549 58 (10.6) 0.00 1 1
Contact type
N Non-household contact 603 76 (12.6) 1 1
N Household contact 1,532 266 (17.4) 0.00 1.5 (1.1–2.0) 1.6 (1.1–2.2)
Duration of close association
N 0–10 years 762 135 (17.7) 1 1
N 11–20 years 690 95 (13.8) 0.7 (0.5–1.0) 1.0 (0.7–1.3)
N 21 years or more 683 112 (16.4) 0.12 0.9 (0.7–1.2) 0.7 (0.5–1.0)
Operational classification of Index cases
N Paucibacillary (PB) 565 76 (13.5) 1 1
N Multibacillary (MB) 1,57 266 (16.9) 0.05 1.3 (0.9–1.9) 1.4 (0.9–2.0)
Sum of family BIs*
N 0–0.9 731 103 (14.1) 1 1
N 1.0–2.9 568 77 (13.6) 1.0 (0.7–1.4) 1.0 (0.7–1.6)
N 3.0–5.5 836 162 (19.4) 0.00 1.5 (1.1–2.0) 1.7 (1.2–2.3)
Notes:
1Based on chi-squared tests.
2Adjustment for clustering and age, gender, presence of BCG scar, type of association with IC, length of time of close association with IC, and sum of family BIs.
3Confidence interval.
*Bacteriological indexes.
doi:10.1371/journal.pntd.0001711.t001
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higher proportion of seropositivity (19.0%) compared with
children (14.8%) and contacts aged .35 years (10.6%) (Table 1).
Interestingly, after BCG vaccination, the 15- to 35-year-old age
group presented a significantly (p=0.02) lower rate of leprosy
(2.5/1,000 PYs) compared with vaccinated PGL-I (+) children
(6.6/1,000 PYs) and contacts over 35 years of age (6.8/1,000 PYs)
(Table 2). In unvaccinated contacts, long periods of association
with the IC and a high family BI were associated with the
development of leprosy (Table 2).
A significantly higher (p,0.01) proportion of PB leprosy cases
was diagnosed in PVCs (4.8%; 13/269) compared with NVCs
(1.9%; 28/1,487). All MB cases occurred among unvaccinated
contacts and were diagnosed at a significantly higher rate
(x
2=8.79; p=0.03) in PUCs (5.5%; 4/73) than in NUCs (0.7%;
2/306) (Figure 2).
Discussion
The predictive value of PGL-I seropositivity in the development
of leprosy in contacts was analyzed as a method of identifying
susceptible individuals among contacts of recently diagnosed
patients. In addition, the possible interference of PGL-I seropos-
itivity with the protective effect of BCG vaccination against leprosy
was investigated.
The observed proportion of seropositivity (16.0%) was similar to
that found in another study performed in Brazil [23]. The
prevalence of seropositivity in this study showed associations with
age and gender similar to those reported in other studies [6][24].
According to Maddison et al. [25], females tend to demonstrate
higher innate IgM levels than males, which may explain the high
female seropositivity rate found in the present study. Independent
of gender, seropositivity rates increased until young adulthood
(15–35 years of age) and decreased in older adults, which is
consistent with the general decrease in overall IgM levels observed
with age [25]. It is well known that leprosy does not manifest
preferentially in women or children, so these high levels are more
likely explained by this common feature of the immune system
rather than specifically reflecting differences in anti-PGL-I
antibody levels in these groups.
The presence of a past BCG vaccination scar was associated
with a higher seropositivity, but the association was weak and
marginally significant when adjusted for covariates. This result
corroborates findings of Baumgart et al. [26], who argued that
BCG vaccination or exposure to tuberculosis or environmental
mycobacteria could interfere with serological tests such as the
PGL-I assay.
In the sample group of this study, PGL-I (+) contacts had a clear
increased risk of developing leprosy. The independent effect of
bacterial load, as measured by the familial BI, on the risk of
developing leprosy among contacts is consistent with previous
findings [19].
The increased incidence of leprosy observed in PVCs and
NUCs during the first year of follow-up suggests subclinical
infection. PVCs were partially benefited by BCG vaccination, as
observed by Bagshawe et al. [18] in children, because they had
insufficient time to build their immune capability to fight M. leprae
but managed to avoid MB leprosy infection. BCG vaccination
induces an increase in interferon-gamma (IFN-c) production,
which is highest among previously vaccinated individuals and
those exposed to environmental mycobacteria [27]. Thus, the
contacts’ immune systems are predisposed to a cellular response
that is effective against M. leprae [28]. IFN-c production in
response to M. leprae antigens is a measure of the ability to mount
an effective immune response against the pathogen [29]. Thus, the
lack of immune response among contacts exposed to the infectious
agent could indicate susceptibility, as posited by Sampaio et al.
[30]. The applicability of PGL-I testing for early diagnosis of
clinical cases thus remains uncertain.
The overall decline in the incidence density of leprosy in
contacts observed after the first year of diagnosis of the ICs, as
observed by other authors [31,32], could result from the treatment
of index and co-prevalent cases. MDT seems to decrease in
infectiousness over time. However, Groenen et al. [14] observed a
Figure 1. Global and stratified incidence density of leprosy cases according to PGL-I serology and BCG vaccination.
doi:10.1371/journal.pntd.0001711.g001
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variation during 4 years of follow-up. This difference may be
explained by the hyperendemicity of the population studied by the
latter authors and the irregular use of treatment by the patients.
The variation in the incidence density of leprosy according to
BCG vaccination status and serological profile indicates that
multiple factors are involved in the development of clinical overt
leprosy in contacts. Together with early diagnosis and the
treatment of ICs and co-prevalent cases, preventive measures
such as contact evaluation, health education and immunization
can prevent the transmission of leprosy.
Interestingly, the early peak in incidence and reduced infection
levels in young adults, which reflect constitutional, age-related
changes in the immune system [33], were only observed in the
vaccinated group. Although the highest leprosy rates were
expected among contacts aged 15–35 years, i.e., in the age group
with the highest seropositivity, this group of contacts had the
lowest incidence rate of leprosy after BCG vaccination. Regardless
of their anti-PGL-I serological status, children are more suscep-
tible than adults to acquiring leprosy infection and developing
overt leprosy due to their incompletely developed immune systems
and close and prolonged contact with possible intra-family sources
of infection [34,35]. Additionally, because BCG vaccination
induces IFN-c production [27], the strong immune response in
young adults will control subclinical infection if present.
The known long incubation period of the disease was confirmed
in the present study, as most of the MB cases occurred in PUCs (4/
6) after the second year of follow-up. However, in the Yalisombo
Study Group [14], the only MB case among the 13 incident cases
in a 4-year cohort of 3207 contacts was diagnosed during the first
year of follow-up. However, because the present study cohort was
alerted to early signs of the disease, the contacts’ awareness and
subsequent detection of leprosy signs may have contributed to the
high proportion of PB cases.
A major limitation of the present study was the use of a non-
probabilistic sample group obtained at a reference leprosy center
under routine conditions. In addition, the sample group may have
had a selection bias toward older individuals, as children did not
usually provide blood samples. However, the group in this study
included contacts with a wide range of social and demographic
characteristics who lived in a medium endemic region, which is
similar to many settings in Brazil. Although it was not possible to
ascertain the number of deaths during follow-up, the mortality rate
due to leprosy is almost negligible within this age group [36]. In
Table 2. Adjusted rate ratios among leprosy contacts, stratified by BCG vaccination after index case diagnosis.
BCG vaccine given subsequent to index case diagnosis
Vaccinated Not vaccinated
Covariates Cases Rate Adjusted
2 rate Cases Rate Adjusted
2 rate
PYs
1 Per Ratios PYs
1 Per Ratios
1,000 (95%CI)
3 1,000 (95%CI)
3
PYs PYs
PGL-I status 41/8,939 4.6 - 19/2,299 8,3 -
N PGL-I Positive 13/919 14.1 4.1 (1.9–8.8) 6/294 20.4 3.2 (1.2–8.1)
N PGL-I Negative 28/7,625 3.7 1.0 13/1,942 6.7 1.0
Previous BCG
N BCG scar present 23/5,572 4.1 1.0 (0.4–2.3) 9/1,199 7.5 0.9 (0.3–2.1)
N No BCG scar 18/3,367 5.3 1.0 10/1,100 9.1 1.0
Age group
N 0–14 years 11/1,679 6.6 2.7(1.1–6.9) 4/478 8.4 2.6 (0.5–12.3)
N 15–35 years 11/4,469 2.5 1.0 9/1,305 6.9 1.0
N 36 years and over 19/2,792 6.8 2.9 (1.2–7.0) 6/516 11.6 1.5 (0.7–3.7)
Contact type
N Non-household contact 6/2,671 2.3 1.0 3/655 4.6 1.0
N Household contact 35/6,322 5.5 2.7 (1.1–6.4) 16/1,644 9.7 1.7 (0.4–7.9)
Duration of close association
N 0–10 years 14/2,928 4.8 1.0 2/675 3.0 1.0
N 11–20 years 11/3,202 3.4 0.9 (0.4–2.0) 7/963 7.3 4.1 (0.8–20.2)
N 21 years or more 16/2,809 5.7 1.2 (0.5–2.9) 10/661 15.1 11.0 (1.7–71.2)
Sum of family BIs*
N 0–2.5 6/5,753 1.0 1.0 6/1,309 4.6 1.0
N 2.6–3.5 10/1,172 8.5 9.3 (3.4–5.5) 4/533 7.5 1.1 (0.3–3.7)
N 3.6 and greater 25/2,013 12.4 10.6 (4.1–27.3) 9/457 19.7 4.1 (1.3–13.1)
1Person years.
2Adjustment for clustering and age, gender, presence of BCG scar, type of association with IC, length of time of close association with IC, and sum of family BIs.
3Confidence interval.
*Bacteriological indexes.
doi:10.1371/journal.pntd.0001711.t002
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antibodies against PGL-I, a precise distinction between positivity
and negativity is sometimes difficult to ascertain. A misinterpre-
tation of results due to grading from 0–4 could, in part, explain the
finding of PB cases among the seronegative contacts.
It is well known that contacts of leprosy patients are at higher
risk of developing leprosy and may even constitute a source of
infection in the community at large [37]. In regions where no
interventions are undertaken, contacts producing antibodies
against M. leprae (corresponding to the PUCs in the present study)
can be considered to be the main indicators of the maintenance of
leprosy’s endemic status. Nevertheless, early and effective inter-
ventions for contacts will affect the disease burden, leading to
exhaustion of cases after 10 years of IC diagnosis.
The present study confirms that contact surveillance and health
education combined with BCG vaccination remain important
strategies for leprosy control. The fact that the highest rate of
leprosy cases was found among PGL-I (+) unvaccinated contacts
justifies targeting this specific group for close monitoring.
Furthermore, it is highly recommended that PGL-I (+) contacts
and contacts with high familial BIs be monitored regardless of
serological response. Targeting these groups for a more focused
and specific approach such as chemoprophylaxis could make this
intervention strategy more cost-effective.
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